High-Cost Drug Evaluation: Dutch Institute Redu...

By HEOR Staff Writer

May 4, 2026

In High-Cost Drug Evaluation, the Dutch Healthcare Institute Zorginstituut Nederland, announced that the aver...
Amgen Financial Results: Q1 2026 Performance Breakdown
NICE Endorses Rozanolixizumab for Myasthenia Gravis Treatment
Accelerating Biotechnology Patient Access in Europe Through Strategic Policy ...
Insulin Substitution Portugal: Implications of Novo Nordisk’s Discontin...
Dementia Pharmacotherapy Guidelines: Emphasizing Non-Pharmacological Approach...
Gaps in AI Governance Healthcare Frameworks: Ensuring Effective Implementatio...
Enhancing Health Technology Assessment Transparency through Digital Innovation
Merck Q1 2026 Performance: Growth and Innovations in Oncology and Cardiometab...
Advancing High-Risk Oncology Interventions: Promising Developments from ASCO ...
Establishing a Vaccine Confidence Strategy: EMA’s New Advisory Group Ta...
Advancing Supply Chain Resilience in Europe’s Off-Patent Medicines Sector
Advancing Subcutaneous Diuretic Therapy for Heart Failure Management